Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207241 | 0.97 | PTGS2 (0.36) | PTGS2PPARGPPARACYP2C9CYP2C19 | |
| SCHEMBL1207238 | 0.81 | PTGS2 (0.41) | PTGS2PPARGPPARACYP2C9CYP2C19 | |
| SCHEMBL5068618 | 0.77 | ALDH1A1 (0.37) | PTGS2ALDH1A1MITFMAPTHTT | |
| SCHEMBL18297950 | 0.76 | HSD11B1 (0.37) | PTGS2PPARGPPARACYP2C9CYP2C19 | |
| SCHEMBL7312533 | 0.76 | GABRA1 (0.35) | ALDH1A1MAPK1CYP2A6TDP1 | |
| SCHEMBL10448876 | 0.76 | ALDH1A1 (0.52) | PTGS2PPARGPPARACYP2C9CYP2C19 | |
| SCHEMBL10581664 | 0.76 | CYP2A6 (0.40) | PTGS2FFAR4ALDH1A1MITFMAPT | |
| SCHEMBL28035602 | 0.75 | TDP1 (0.41) | PTGS2PPARGPPARACYP2C9CYP2C19 | |
| SCHEMBL9461 | 0.74 | MAPK1 (0.43) | CYP2C9CYP2C19ALDH1A1MAPTKMT2A | |
| SCHEMBL28562495 | 0.74 | MAPK1 (0.43) | PTGS2FFAR4ALDH1A1MITFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | claimed |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-05-26 | — | — | US | claimed |
| US-20140243210-A1 | PURIFICATION OF IMMUNOGLOBULINS USING AFFINITY CHROMATOGRAPHY AND PEPTIDE LIGANDS | CARBONELL RUBEN (US) | 2014-08-28 | — | — | US | claimed |
| US-20090005261-A1 | PURIFICATION OF IMMUNOGLOBULINS USING AFFINITY CHROMATOGRAPHY AND PEPTIDE LIGANDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-01-01 | — | — | US | claimed |
| EP-1472372-A4 | METHODS FOR THE PREPARATION OF CHEMICALLY MISAMINOACYLATED tRNA VIA PROTECTIVE GROUPS | AMBERGEN INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-7408030-B2 | Peptide that binds to the Fc region of an antibody; from liquid containing immunoglobulins such as blood or blood plasma, plasma fractions, ascites fluid, aqueous cell culture, milk, and colostrums | NORTH CAROLINA STATE UNIVERSITY (US) | 2008-08-05 | — | — | US | claimed |
| US-7288372-B2 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. (US) | 2007-10-30 | — | — | US | claimed |
| US-20060153834-A1 | Peptide that binds to the Fc region of an antibody; from liquid containing immunoglobulins such as blood or blood plasma, plasma fractions, ascites fluid, aqueous cell culture, milk, and colostrums | NORTH CAROLINA STATE UNIVERSITY | 2006-07-13 | — | — | US | claimed |
| EP-1472372-A1 | METHODS FOR THE PREPARATION OF CHEMICALLY MISAMINOACYLATED tRNA VIA PROTECTIVE GROUPS | Ambergen, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030219780-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. | 2003-11-27 | — | — | US | claimed |
| EP-0764152-B1 | SUBSTITUTED INDOLYLMETHYLENE-OXINDOLE ANALOGUES AS TYROSINE KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-07-31 | — | — | EP | claimed |
| US-6096861-A | CHEMICAL COMPLEX; MODELS FOR THE DESIGN OF IONOPHORES WHICH CAN INTRODUCE METAL CATIONS INTO CELLS AND ORGANELLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-01 | — | — | US | claimed |
| US-5977302-A | SOLUTION PHASE SYNTHESIS PERMITTING LARGE SCALE BULK PRODUCTION USING A MINIMUM NUMBER OF STEPS; REDUCED UNWANTED SIDE REACTIONS AND ELIMINATION OF SIDE CHAIN PROTECTION STEPS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0623626-B1 | Automated allyl deprotection in solid-phase synthesis | PERSEPTIVE BIOSYSTEMS INC (US) | 1999-09-01 | — | — | EP | claimed |
| WO-1999026964-A1 | LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1998041537-A1 | PEPTIDE-PEPTOID METAL COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-09-24 | — | — | WO | claimed |
| US-5777077-A | SINGLE PHASE LIQUID SOLUTION OF A SOLUBLE ORGANOPALLADIUM COMPLEX CATALYST, A CARBOXYLIC ACID AND AN ACCEPTOR E.G. DIMEDONE, N-METHYLANILINE, N,N'-DIMETHYLBARBITURIC ACID, MORPHOLINE OR N-METHYLMORPHOLINE; SIDE EFFECT REDUCTION | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1998-07-07 | — | — | US | claimed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | claimed |
| EP-0623626-A1 | Automated allyl deprotection in solid-phase synthesis | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1994-11-09 | — | — | EP | claimed |
| EP-0518295-A2 | Allyl side chain protection in peptide synthesis | MILLIPORE CORPORATION (US) | 1992-12-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | VIP, HABP2, DPP9 | PTGS2 2747/4885PPARG 4643/4885PPARA 4667/4885 |
| US-20030219780-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | NSUN3, TRMT1, TARBP1 | PTGS2 2964/4885PPARG 3392/4885PPARA 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.